EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Alexander Disease: A Literature Review for Clinicians

Maria Tozzo Pesco iD, Jun Xie, Eleonora Silvana D'Ambrosio

Journal of Child Neurology · 2026-07 · 41 (6) · 911-921

DOI: 10.1177/08830738261422840 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Child Neurology, online erschienen am 16.03.2026. Verfasst von Maria Tozzo Pesco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Department, UMass Chan Medical School, Worcester, MA, USA. Hauptthemen laut MEDLINE: Alexander Disease. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alexander disease (ALEXD; MIM 203450) is a rare leukodystrophy caused by dominant mutations in the GFAP ( Glial Fibrillary Acidic Protein ) gene, which encodes a key structural protein of astrocytes. First described in 1949, ALEXD is now recognized as a clinically heterogeneous disorder with a broad phenotypic spectrum spanning neonatal, infantile, juvenile, and adult-onset forms. Clinical manifestations vary according to age at onset and disease subtype, ranging from early developmental impairment and progressive neurologic decline to later-onset presentations dominated by bulbar dysfunction, ataxia, and spinal cord involvement. Diagnosis can be challenging because of phenotypic overlap with other neurologic conditions; however, characteristic magnetic resonance imaging patterns combined with molecular confirmation of GFAP mutations are central to diagnosis. To date, more than 100 GFAP mutations have been reported, although robust genotype-phenotype correlations remain elusive. Pathogenic GFAP variants lead to astrocyte dysfunction through protein aggregation, oxidative stress, and cytoskeletal disorganization, resulting in Rosenthal fiber formation. Elevated GFAP levels in cerebrospinal fluid have emerged as a potential biomarker, though their clinical utility remains under investigation. Current management is supportive, but emerging gene-targeted approaches, including antisense oligonucleotides such as zilganersen and AAV-mediated gene silencing strategies, offer promising therapeutic prospects. This review provides an updated overview of the clinical, radiologic, genetic, and molecular features of ALEXD, emphasizing its spectrum of phenotypes across age groups and ongoing efforts toward improved diagnosis and targeted treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alexander DiseaseHumansGlial Fibrillary Acidic ProteinMutation

Stichwörter der Autor:innen

MRIdevelopmental delaygeneticsotherseizures

Substanzen

Glial Fibrillary Acidic ProteinGFAP protein, human

Autor:innen und Institutionen

  • Gene Therapy Department, UMass Chan Medical School, Worcester, MA, USA.
  • Neurology Department, UMass Chan Medical School, Worcester, MA, USA.

ORCID-Profile: Maria Tozzo Pesco

Zitieren

APA

Pesco, M. T., Xie, J., & D'Ambrosio, E. S. (2026). Alexander Disease: A Literature Review for Clinicians. Journal of Child Neurology, 41(6), 911-921. https://doi.org/10.1177/08830738261422840

Vancouver

Pesco MT, Xie J, D'Ambrosio ES. Alexander Disease: A Literature Review for Clinicians. Journal of Child Neurology. 2026;41(6):911-921. doi:10.1177/08830738261422840

BibTeX
@article{Pesco2026,
  author = {Pesco, Maria Tozzo and Xie, Jun and D'Ambrosio, Eleonora Silvana},
  title = {Alexander Disease: A Literature Review for Clinicians},
  journal = {Journal of Child Neurology},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {911--921},
  doi = {10.1177/08830738261422840}
}
Kostenlos starten →